Do we need more IL-17 and JAK Inhibitors in Spondyloarthritis?
Dr. Eric Ruderman shares his perspectives on the following abstracts being presented at Eular 2024 in Vienna, Austria:
OP0195 Sonelokimab IL 17 A/F nanobody inhibitor
LB0005 Izokibep IL17A nanobody inhibitor
POS0803 Vunakizumab, another IL17A inhibitor
OP0138 TAK-279 phase 2B selective TYK2 inhibitor Zasocitinib
JAK Inhibitors for New Indications
Dr. Janet Pope discusses new indications for JAK inhibitors, reporting from Eular 2024 in Vienna, Austria.
PsA Treatment: is Earlier Better?
Dr. Aurelie Najm discusses abstract OP0184, presented at Eular 2024 in Vienna, Austria.
Transition from Psoriasis to PsA: Can we Prevent It?
Dr. Aurelie Najm discusses abstract OP0010 presented at Eular 2024 in Vienna, Austria.
Depression and Anxiety Associated with Inability to Achieve Remission in RA and PsA
Dr. Aurelie Najm reports on abstract POS0946 presented at Eular 2024 in Vienna, Austria.
PsA Switch or Cycle, the Eternal Question
Dr. Aurelie Najm reports on abstracts POS0278 and POS0266 presented at Eular 2024 in Vienna, Austria.
Axial & Psoriatic Disease
Dr. Peter Nash at Eular 2024 in Vienna, Austria.
Difficult to Treat Psoriatic Arthritis
Dr. Peter Nash reports at Eular 2024 in Vienna, Austria.
Predictors of Treatment Response in Psoriatic Arthritis
Dr. Janet Pope reviews three abstracts presented at Eular 2024 in Vienna, Austria. Abstracts discussed: 
POS 0990
POS 0992
POS 0266
Prevention of Psoriatic Arthritis
Dr. Peter Nash sharing his perspectives on preventing psoriasis from turning into PsA at Eular 2024 in Vienna, Austria.